Seminar

22 November 2017: Seminar on Biosimilars & Competition Law

22 November 2017: Seminar on Biosimilars & Competition Law

22 November 2017: Seminar on Biosimilars & Competition Law

16.10.2017 NL law

On Wednesday 22 November 2017, Stibbe will organise a seminar on Biosimilars & Competition Law in Brussels. This seminar will be co-organized by competition lawyers from Stibbe and competition economists from CRA so as to cover both legal and economic angles relevant to this increasingly important field. 

Given the ever increasing economic significance of biologics in the pharmaceutical space – as well as signals from regulators that this field will come into focus shortly – it  is time to explore the implications of the competition rules for business behavior in this area. This includes a discussion of the following topics/questions: 

  • What can we expect from competition authorities in this space?
  • To what extent do the competition law principles developed for synthetic drugs apply to the biological space?
  • How does this play out in the context of life cycle management?  
  • What stance do authorities take in merger control cases involving biologics?
  • What about pricing strategies? Is there more reason for concern following cases like Aspen (EU) and Pfizer (UK)?

Our intention is to go beyond scratching the surface on these topics in order to provide guidance for pharmaceutical companies in an area which we feel is receiving insufficient attention in the competition law domain. 

For more information and to register, please send an email to: StibbeEvents@Stibbe.com.

A provisional program can be found below: 

  • 12:00 - 12:30: Registration
  • 12:30 - 12:45:  Introduction by chair - Stibbe/CRA
  • 12:45 - 13:15: Keynote speech by Paul Paul Csiszár, Director of "Basic Industries, Manufacturing and Agriculture", responsible for the Commission’s pharma unit
  • 13:15 - 13:45: Industry trends in biosimilars - Tim Wilsdon, CRA  
  • 13:45 - 14:30: Biologics in EU merger control: current status and likely issues in the future - Stibbe
  • 14:30 - 15:00: Break
  • 15:00 - 15:45: Competition law boundaries of life cycle management strategies: application to the biologics space - Stibbe
  • 15:45 - 16:30: Pricing practices & antitrust: law and economics - Raphaël De Coninck, CRA
  • 16:30 - 16: 45: Closing
  • 16:45 - 17:30: Drink

When: 22 November 2017 from 12.00 -17.30.

Where: Stibbe office: Central Plaza - Loksumstraat 25 Rue de Loxum - 1000 Brussels

stibbe_logo_background_01    logo - CRA

 

Team

Related news

12.05.2020 NL law
Kroniek van het mededingingsrecht

Articles - Wat de gevolgen van de coronacrisis zullen zijn voor de samenleving, de economie en – laat staan – het mededingingsbeleid laat zich op het moment van de totstandkoming van deze kroniek niet voorspellen. Wel stond al vast dat het mededingingsrecht zal worden herijkt op basis van de fundamentele uitdagingen die voortvloeien uit zich ontwikkelende ideeën over het belang van industriepolitiek, klimaatverandering en de positie van tech-ondernemingen en de platforms die zij exploiteren.

Read more

07.05.2020 NL law
Spreading fast: Dutch and Belgian COVID-19 State-aid approved

Short Reads - Many Member States are taking measures to support the economy during the COVID-19 crisis. The European Commission’s Temporary Framework enables the rapid approval of certain types of State aid. So far, three Dutch State aid schemes and six Belgian schemes were approved, providing the beneficiaries with legal certainty that the aid received is in line with EU State aid law and cannot be challenged at a later stage.

Read more

07.05.2020 NL law
ECJ confirms: no shortcut for ‘by object’ antitrust infringements

Short Reads - The European Court of Justice has found there is no shortcut for determining whether particular conduct can be held to have the object to restrict competition. A competition authority will always need to assess carefully whether the conduct reveals "a sufficient degree of harm to competition” before labelling it a ‘by object’ infringement. This is the case where there is sufficiently solid and reliable experience showing that this type of conduct is commonly regarded as being inherently anticompetitive.

Read more

28.04.2020 EU law
Origin of the primary ingredient - Implementing Regulation 2018/775

Short Reads - Since the beginning of this month, the origin of the primary ingredient of a food must be clearly indicated on the product when it differs from the origin given for the product as a whole. This is the result of the implementation of Article 26 (3) of the European Regulation 1169/2011 on the provision of food information to consumers.  

Read more

07.05.2020 NL law
COVID-19: fast-forwarding competition law

Short Reads - Competition authorities are temporarily ‘green-lighting’ certain collaboration initiatives to safeguard the supply of essential products in light of the COVID-19 outbreak. At the same time, authorities warn against using the current exceptional circumstances to engage in anti-competitive practices, such as price-fixing, excessive pricing, refusals to deal or opportunistic takeovers. 

Read more

This website uses cookies. Some of these cookies are essential for the technical functioning of our website and you cannot disable these cookies if you want to read our website. We also use functional cookies to ensure the website functions properly and analytical cookies to personalise content and to analyse our traffic. You can either accept or refuse these functional and analytical cookies.

Privacy – en cookieverklaring